Rituxan (rituximab) - Roche
siplizumab (TCD601) - ITBMed
cyclophosphamide - Generic mfg.
fludarabine IV - Generic mfg.
Delayed Tolerance Through Mixed Chimerism (clinicaltrials.gov) - Sep 29, 2026 - P1/2 | N=20 | Recruiting | Sponsor: Massachusetts General Hospital | Active, not recruiting ➔ Recruiting | Trial completion date: Dec 2030 ➔ Dec 2032 | Trial primary completion date: Dec 2028 ➔ Dec 2031 
Enrollment open • Trial completion date • Trial primary completion date • Renal Disease • Transplantation • CD34
http://clinicaltrials.gov/ct2/show/NCT05900401
 
Sep 29, 2026
 
Prev Next